ANNEX I. SUMMARY OF PRODUCT CHARACTERISTICS. 1 INTEGRILIN is indicated for the prevention of early myocardial infarction in adults presenting. Package leaflet: Information for the patient. Integrilin mg/ml solution for infusion eptifibatide. Read all of this leaflet carefully before you start using this. 1. Package leaflet: Information for the patient. Eptifibatide Accord 2 mg/ml solution for injection eptifibatide. Read all of this leaflet carefully before you start using.
|Published (Last):||14 October 2017|
|PDF File Size:||7.58 Mb|
|ePub File Size:||20.50 Mb|
|Price:||Free* [*Free Regsitration Required]|
To view content sources and attributions, please refer to our editorial policy. Treatment with Eptifibatide prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization i. Intracranial Hemorrhage and Stroke.
Subscribe to receive email notifications whenever new articles are published. Population pharmacokinetics PK and pharmacodynamics PD of integrelin, a platelet aggregation inhibitor. Prevention of acute reocclusion after thrombolysis with IV recombinant tissue plasminogen activator. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. In addition there was 1 case of cerebral infarction in the Eptifibatide Injection group.
Early sheath removal is encouraged while Integrilin is being infused. The safety and efficacy of Eptifibatide Injection in patients dependent on dialysis has not been established. By clicking Subscribe, I agree to the Drugs. There was no apparent difference in efficacy between older and younger patients treated with Integrilin.
This relationship was most apparent for patients weighing less than 70 kg. Clinical pharmacology of eptifibatide. The need for thrombotic “bailout” was significantly reduced with eptifibatide at 48 hours 2.
Integrilin Monograph for Professionals –
Loscalzo J, Braunwald E. A loading dose of clopidogrel, prasugrel, or ticagrelor also is recommended prior to PCI in patients undergoing stent placement. The most common bleeding complications were related to cardiac revascularization CABG-related or femoral artery access site bleeding. Caution when used in patients requiring thrombolytic therapy.
These studies revealed no evidence of harm to the fetus due to eptifibatide. Acute profound thrombocytopenia, as well as immune-mediated thrombocytopenia, has been reported [see Adverse Reactions 6. Heparin use is discouraged after the PCI procedure. In addition there was 1 case of cerebral infarction in the Integrilin group. Ibsert of receptor occupancy and platelet aggregation response of eptifibatide administered intravenously in patients with unstable angina or non-Q-wave myocardial infarction.
Adjunct to anticoagulant therapy e.
Eptifibatide Injection – FDA prescribing information, side effects and uses
Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. These 16, patients had a mean age of 62 years range: Possible additive pharmacologic effects 1 4. These findings suggest acute thrombocytopenia after the administration of Integrilin can develop as a result of naturally occurring drug-dependent antibodies or those induced by prior exposure to Integrilin.
Fatal bleeding reactions have been reported. Most major bleeding associated with Eptifibatide Injection has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract.
Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: The need for thrombotic “bailout” was significantly reduced with Integrilin at 48 hours 2.
Table 5 also shows the incidence of the intsgrilin of the itegrilin endpoint, death whether or not preceded by an MI and new MI in surviving patients at 30 days. Safety and effectiveness of Integrilin in pediatric patients have not been studied.